In spite of the burden psoriasis brings and
recent important strides in psoriasis care,
psoriasis research does not receive the federal
funding that it deserves. With only about $1 per
patient spent by the federal government annually
on psoriasis research, developments have not kept
pace with the needs of the millions of Americans
affected by this disease.
The National Psoriasis Foundation is committed
to building a greater federal government
investment in psoriasis research to improve
access to treatments and move faster toward a
cure. Through education of policy-makers,
legislative action and grassroots activity, we
know it is possible to strengthen and expand
psoriasis research and access to care, and that a
cure is on the horizon. Long a "silent"
community, we are now active in Washington, D.C.,
and in federal congressional districts around the
country, advocating for changes that will
catapult us forward toward better treatments, a
cure and improved quality of life for everyone
affected by psoriasis.
Public policy
agenda |
110th Congress 2nd session
(2008)
|
 | 2008 ask sheet:
House and Senate (171k PDF) |
110th Congress 1st session
(2007)
|
| 2007 ask sheet: House (120k PDF) |
| 2007 ask sheet: Senate (110k PDF) |
109th Congress 2nd session
(2006)
|
|
National Psoriasis Foundation
2006 public policy agenda (91k PDF) |
109th Congress 1st session
(2005)
|
|
National Psoriasis Foundation
2005 public affairs agenda (191k PDF) |
Legislation |
110th Congress
(2007-2008)
|
| Psoriasis and Psoriatic
Arthritis Research, Cure, and Care Act (PPARCCA)
of 2007
This bipartisan bill calls upon the National
Institutes of Health (NIH) and the Centers for
Disease Control and Prevention (CDC) to build
their work in psoriasis and psoriatic arthritis
by:
- Expanding biomedical research
- Building CDC data collection / patient
registry
- Calling for a federal summit on
psoriasis
- Requiring an Institute of Medicine
report on access to care
Psoriasis and Psoriatic Arthritis Research,
Cure, and Care Act of 2007 bill
summary (93k
PDF)
Ful
l coverage of PPARCCA
|
|
|
109th Congress
(2005-2006)
|
| House
Concurrent Resolution 340 (H. Res.
340) |
|
H. Res. 340: Expressing the sense of the
Congress with respect to the effective treatment
of and access to care for individuals with
psoriasis and psoriatic arthritis, and for other
purposes. (28k PDF) |
| Senate
Resolution 420 (S. Res. 420) |
|
S. Res. 420: Expressing the sense of the
Senate that effective treatment and access to
care for individuals with psoriasis and psoriatic
arthritis should be
improved. (30k PDF) |
| Senate
Resolution 206 (S. Res. 206) |
|
S. Res. 206: Designating August 2005 as
Psoriasis Awareness Month (21k PDF) |
Federal funding for
psoriasis
|
110th Congress
(2007-2008)
|
| Congressional
correspondence |
| House "Dear Colleague" letter
calling for increased funding for psoriasis and
psoriatic arthritis research at the National
Institutes of Health (NIH) (53k PDF) |
| House sign-on letter: Labor
Health & Human Services (LHHS)
appropriations Feb. 22, 2007 (7k
PDF) |
|
NIH response to Rep. Jim
Gerlach, R-Penn. March 27, 2007 (326k
PDF) |
|
Letter from Rep. Gerlach,
R-Penn., to NIH, requesting psoriasis
audit Jan.
17, 2007 (356k PDF) |
| National
Psoriasis Foundation correspondence |
|
Written testimony from the
National Psoriasis Foundation to the House LHHS
Appropriations Subcommittee regarding FY2008
funding for psoriasis and psoriatic arthritis
research March 30, 2007 (127k
PDF) |
109th Congress
(2005-2006)
|
| Congressional
correspondence |
|
House "Dear Colleague"
letter calling for increased funding for
psoriasis and psoriatic arthritis research at the
NIH March 16,
2006 (160k PDF) |
|
House sign-on letter: LHHS
appropriations March 8, 2006 (183k
PDF) |
|
Letter from Rep. David
Scott, R-Ga., re: House LHHS appropriations bill
report language March 31, 2006 (301k
PDF) |
|
Letters from Sen.
Edward Kennedy, D-Mass., to Centers for Disease
Control and Prevention (CDC) and National
Institute of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS) March 29, 2006 (776k
PDF) |
|
Letter from Sen. Chuck
Grassley, R-Iowa, to CDC March 16, 2006 (68k
PDF) |
|
NIH response to Rep. Jim
Gerlach, R-Penn. Jan. 3, 2006 (85k
PDF) |
|
Letter from Rep.
Gerlach, R-Penn., to NIH, requesting psoriasis
audit Dec. 1,
2005 (124k PDF) |
| National
Psoriasis Foundation correspondence |
|
Written testimony from the
National Psoriasis Foundation to the Senate LHHS
Appropriations Subcommittee regarding FY2007
funding for psoriasis and psoriatic arthritis
research April 26, 2006 (242k
PDF) |
|
Written testimony from the
National Psoriasis Foundation to the House LHHS
Appropriations Subcommittee regarding FY2007
funding for psoriasis and psoriatic arthritis
research March 30, 2006 (273k
PDF) |
Issue briefs, facts sheets and
white papers
|
110th Congress
(2007-2008)
|
|
Analy
sis of 2006 NIH Psoriasis and Psoriatic Arthritis
Funded Research (721k PDF) |
|
Psoriasis access to care issue
brief (301k
PDF) |
|
Psoriasis and co-morbid
conditions issue brief (325k PDF) |
|
Psoriasis and mental
health issue brief (298k PDF) |
|
Psoriasis research
issue brief (397k PDF) |
|
Research activities
at the National Psoriasis
Foundation (314k PDF) |
| State fact
sheets |
109th Congress
(2005-2006)
|
|
Psoriasis access to care issue
brief (1.7m
PDF) |
|
Psoriasis research issue
brief (244k
PDF) |
Federal agency and regulatory
advocacy
|
|
Psoriasis Foundation
Senior Director of Advocacy and External Affairs
testifies before Food and Drug Administration
(FDA) re: use of etanercept in pediatric
population June 18, 2008 (94k
PDF) |
|
Psoriasis Foundation member Kelsey Larson testifies before Food and Drug Administration (FDA) re: use of etanercept in pediatric population June 18, 2008 (79k
PDF) |
|
Psoriasis Foundation Board member Dan Farrington testifies before Food and Drug Administration (FDA) re: ustekinumab June 17, 2008 (93k
PDF) |
|
Psoriasis Foundation member Ellen Clements testifies before Food and Drug Administration (FDA) re: ustekinumab June 17, 2008 (97k
PDF) |
